The Commercial Model Behind Winning Robotics Companies! Insights From @henryapeck of @lsintelligence
Episode 427: This Month in MedTech: What $4B in Exits Signals About the Next MedTech Cycle with Henry Peck of LSI
Why Surgical Robots Protect Billions in Implant Revenue! Insights From @henryapeck of @lsintelligence
Episode 427: This Month in MedTech: What $4B in Exits Signals About the Next MedTech Cycle with Henry Peck of LSI
Why Stryker Invested $400M Instead of Buying CMR Surgical! Insights From @henryapeck of @lsintelligence
Episode 427: This Month in MedTech: What $4B in Exits Signals About the Next MedTech Cycle with Henry Peck of LSI
Why Starting Another Orthopedic Robot May Be a Mistake! Insights From @henryapeck of @lsintelligence
Episode 427: This Month in MedTech: What $4B in Exits Signals About the Next MedTech Cycle with Henry Peck of LSI
If You’ve Never Been in a Hospital, How Do You Market It?
Episode 429: MedTech Investing: What Makes Intuitive Ventures Bet $5M to $10M with Terri Burke
Type 2 Diabetes: Shocking results on how this procedure is impacting A1C in diabetics with Bob Haggerty, CEO of Aqua Medical.
What if Type 2 diabetes could eventually be treated through an endoscope?
I sat down with Bob Haggerty, President and CEO of Aqua Medical @aqua_endoscopy , to unpack one of the more interesting new categories emerging in MedTech: Endoscopic Metabolic Restoration.
Aqua is developing an investigational procedure that passes directly through a standard endoscope and uses water vapor to treat the proximal small intestine, an area involved in nutrient sensing and glycemic control.
The early clinical signal is what caught my attention.
Bob discusses a 66-patient international program where Aqua observed average A1C reductions in the roughly 2.1 to 2.6-point range at one year.
But the bigger conversation is about where a procedure like this could fit into diabetes care.
We talked about GLP-1s, oral medications, insulin, lifestyle modification, and why the future may not be device versus pharma. For many patients, the better model could be complementary therapies that reduce disease burden from multiple directions.
We also went deep on the MedTech side: why Aqua designed the technology to fit through existing endoscopes, how it could integrate into ASC workflow, the economics of chronic diabetes care, its Series B financing, the U.S. clinical pathway, upcoming pivotal work, and what commercialization could eventually look like.
A fascinating example of what happens when GI innovation starts moving beyond diagnosis and into metabolic therapy.
Episode Breakdown:
00:00 Can Type 2 Diabetes Be Treated Without Lifelong Medication?
01:31 Meet Bob Haggerty, CEO of Aqua Medical
03:10 Bob Haggerty's Journey in Medical Devices and GI Innovation
04:40 Why Type 2 Diabetes Needs Better Treatment Options
05:20 Why Medical Devices Could Reduce Dependence on Medication
06:26 What Is Endoscopic Metabolic Restoration?
07:20 How Treating the Small Intestine Could Improve Blood Sugar Control
08:53 Can Aqua Medical's Treatment Lower HbA1c?
09:34 Clinical Trial Results: Up to 2.6 Percentage Point HbA1c Reduction
10:10 Market Engineering and MedTech Growth
12:42 Can Endoscopic Treatment Work Alongside Diabetes Medication?
13:34 How Does Aqua Medical Compare With GLP-1 Drugs?
14:20 Why GLP-1 Side Effects Create Demand for Other Treatments
15:41 Could Diabetes Treatment Become a Simple Outpatient Procedure?
16:19 How Aqua Medical Fits Into Existing Endoscopy Workflows
17:00 Aqua Medical's Water Vapor Treatment Demonstration
17:39 How Steam Ablation Treats the Small Intestine
19:08 How Does the Procedure Affect Blood Sugar Regulation?
20:00 Understanding HbA1c and the Risks of High Blood Sugar
21:28 The Economic Burden of Type 2 Diabetes
21:51 Could a One-Hour Procedure Reduce Diabetes Healthcare Costs?
23:24 Aqua Medical's Series B Funding and FDA Clinical Trials
24:36 When Could Aqua Medical Receive FDA Approval?
25:39 Could Diabetes Eventually Be Treated With a Procedure?
27:04 The Future of Preventive Metabolic Healthcare
28:08 Why Aqua Medical's Through-the-Scope Design Matters
28:28 Making Diabetes Treatment Easier for GI Physicians
29:51 The Leading Endoscopy Manufacturers: Olympus, Fujifilm and Pentax
31:25 How Aqua Medical Is Improving Its Technology
32:39 Upcoming Clinical Trials and MedTech Conferences
34:11 Final Thoughts and Where to Learn More
35:22 End
Silicon Valley’s AI Money Is Moving Into the Physical World! Insights from @OmarMKhateeb
Episode 425: Why AI Could Trigger the Next MedTech Investment Boom: a16z State of Markets 2026!
Short-Term Revenue Can Destroy Long-Term Focus! Insights from @nickdamian0 , Co-founder and CEO of @andromedasurg , and @DaveMessina , General Partner at @pioneer_fund
Episode 426: Autonomous Surgery: Andromeda Surgical’s New MedTech Playbook with Nick Damiano & Dave Messina
4 Stakeholders Behind Billion-Dollar Healthcare Companies! Learn With @CaristoHeart
Episode 428: Can AI Predict Heart Attacks? The Future of Coronary Imaging | Steve Deitsch, Caristo CEO!
Could Heart Risk Be Found Before Symptoms Appear? Learn With @CaristoHeart
Episode 428: Can AI Predict Heart Attacks? The Future of Coronary Imaging | Steve Deitsch, Caristo CEO!
Drug Developers Can Now Target Heart Inflammation Directly! Learn With @CaristoHeart
Episode 428: Can AI Predict Heart Attacks? The Future of Coronary Imaging | Steve Deitsch, Caristo CEO!
Why Capital Allocation Matters More Than Expense Reports! Learn With @CaristoHeart
Episode 428: Can AI Predict Heart Attacks? The Future of Coronary Imaging | Steve Deitsch, Caristo CEO!
MedTech Investing: What Makes Intuitive Ventures Bet $5M to $10M with Terri Burke!
The real MedTech funding test is not whether the technology is impressive. It is whether the business can win.
I sat down with Terri Burke, Senior Partner at Intuitive Ventures, to unpack how they evaluate the next generation of MedTech and healthcare innovation.
Intuitive Ventures can invest from seed through growth, with initial checks typically ranging from $5M to $10M. But capital does not follow technology alone.
Terri looks at the clinical problem, patient impact, evidence, physician workflow, economics, business model, market, team, and potential paths to an eventual return.
We also got into AI in cardiology and imaging, where she sees real potential to extract more value from existing clinical data. The important distinction is that AI still needs a clinical rationale and a business model. Adding AI to a product does not automatically make it valuable.
One of my favorite parts of the conversation was the distinction between a product and a business. A technology can be useful to physicians and still not create the type of company institutional investors can back.
We also discussed why category-defining companies stand out, what founders should prove before Series A, why first-in-human data can become an important inflection point, how to build relationships with VCs before fundraising, and why founders should start building their brand long before commercialization.
Terri has sat on the operator, founder, and investor sides of MedTech, and that perspective makes this a valuable conversation for anyone trying to understand what actually makes healthcare innovation investable.
Episode Breakdown:
00:00 Why Game-Changing MedTech Starts With the Right Problem
00:45 Intro
01:05 Meet Terri Burke, Senior Partner at Intuitive Ventures
02:09 From MedTech Operator to Founder and Venture Investor
04:52 The Biggest Lesson From Building and Exiting a Startup
06:02 Why Great Service Providers Matter to MedTech Founders
07:22 Why Operating Experience Makes Better Investors
08:51 What MedTech Leaders Can Learn From Frontline Experience
10:08 Market Engineering and MedTech Growth
12:15 Why MedTech Leaders Must Understand Their Customers
13:26 Why You Cannot Build a Market Without Being in It
15:01 Inside Intuitive Ventures' Investment Philosophy
15:30 Why Intuitive Ventures Invests Beyond Surgical Robotics
16:55 Intuitive's Quintuple Aim and the Future of Patient Care
18:07 Why Intuitive Ventures Is Different From Traditional Corporate VC
20:08 Why Early-Stage MedTech Funding Is Getting Harder
20:45 How Intuitive Ventures Supports Its Portfolio Companies
22:16 What Does a $5 Million to $10 Million MedTech Investment Look Like?
22:50 How Intuitive Ventures Evaluates Startups and Potential Exits
24:33 Intuitive Ventures' Investment Funds and the OrganOx Exit
25:25 How Intuitive Ventures' Investment Strategy Is Evolving
27:24 What Makes a HealthTech Company Worth Investing In?
28:10 Why Clinical Value Matters More Than AI Hype
29:42 Why Medical Device Cybersecurity Is a Growing Opportunity
30:26 Where AI Could Create the Most Value in MedTech
31:19 How AI Could Transform Cardiology and Clinical Decision-Making
32:39 Why AI Healthcare Startups Need Sustainable Business Models
33:39 Can Platform-Based MedTech Companies Attract Venture Capital?
34:16 Stop Pitching Technology and Start Pitching Solutions
35:31 Why Category Creation Matters for MedTech Startups
36:42 How to Prove Market Demand Before Commercialization
38:01 Why Seed-Stage MedTech Companies Struggle to Raise Capital
38:45 What Separates Fundable MedTech Startups From the Rest?
39:37 The Difference Between a Great Product and a Great Business
41:24 Why MedTech Founders Must Reverse Engineer Their Exit Strategy
42:09 How to Validate Your Market Before Building a Product
43:02 What Early Traction Do MedTech Investors Want to See?
43:27 How to Pitch a MedTech Startup With Limited Clinical Data
44:41 Why Market-Product Fit Should Come Before Product-Market Fit
45:57 Why Investors Want Category-Defining Innovation
46:56 How HATICOR Is Targeting an Underserved Cardiology Market
48:07 Inside the Intuitive Ventures Investment Portfolio
49:03 Emerging Opportunities in Neuromodulation and Medical Devices
51:04 Why Founders Should Research Investors Before Pitching
52:07 How to Build Relationships With Venture Capital Investors
53:51 Why LinkedIn Matters for MedTech Fundraising
54:07 Why MedTech Startups Should Build Their Brand Early
55:05 Why Waiting Until Commercialization to Start Marketing Is a Mistake
56:11 How Founders Can Shape Their Company's Market Narrative
56:58 Why Branding Is More Than Logos and Colors
57:12 How Terri Burke Approaches Mentorship and Learning
57:43 Why Strong Relationships Create Long-Term Career Value
59:14 How to Build Meaningful Professional Relationships
01:00:40 Why Personal Connections Matter in Business
01:01:56 How MedTech Founders Can Pitch Intuitive Ventures
01:02:12 Why Warm Introductions Get Investors' Attention
01:03:09 How Founders Can Build Connections With Venture Capitalists
01:04:12 What Intuitive Ventures Looks for in MedTech Startups
01:05:15 Final Advice for MedTech Founders and Entrepreneurs
01:05:44 Closing Remarks and Where to Find Intuitive Ventures
01:06:00 End
Our CEO, Steve Deitsch, joins @OmarMKhateeb on @StateofMedTech podcast to discuss why cardiovascular care is moving beyond traditional measures, and how FDA-authorized CaRi-Heart brings coronary inflammation into routine CCTA, helping transform how cardiovascular disease is managed.
Tune in for insights on:
📌Improving outcomes for patients and creating value for clinicians and payers
📌Enabling cardiovascular disease prevention
📌Commercializing category-defining innovation that creates measurable impact
The future of cardiology is looking beyond just the plaque.